ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Glycogenesys Inc.  (MM)

Glycogenesys Inc. (MM) (GLGS)

0,00
0,00
(0,00%)
Geschlossen 21 Januar 10:00PM
0,00
0,00
(0,00%)
Nach Börsenschluss: -

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Wichtige Statistiken und Details

Current Price
-
Gebot
-
Fragen
-
Volumen
-
0,00 Tagesbereich 0,00
0,00 52-Wochen-Bereich 0,00
Handelsende
-
Handelsbeginn
-
Letzte Trade
Letzter Handelszeitpunkt
Durchschnittliches Volumen (3 Mio.)
-
Finanzvolumen
-
VWAP
-

GLGS Neueste Nachrichten

GlycoGenesys, Inc. Announces Chapter 11 Filing, Reduction in Work Force and Senior Management Changes

Company Significantly Reduces Expenses To Pursue Strategic Alternatives While Maintaining Multiple Myeloma Clinical Trial BOSTON, Feb. 3 /PRNewswire-FirstCall/ -- GlycoGenesys, Inc...

GlycoGenesys, Inc. Requests Hearing to Appeal Nasdaq Staff Determination

GlycoGenesys, Inc. (NASDAQ:GLGS), a biotechnology company, today announced that it requested a hearing before a Nasdaq Listing Qualifications Panel to appeal the Nasdaq Staff...

GlycoGenesys, Inc. Comments on 2005 Third Quarter Financial Results and Stock Listing Status; Quarterly Conference Call Schedule

GlycoGenesys, Inc. (NASDAQ:GLGS), a biotechnology company focused on drug development, today commented on results from its Form 10-Q for the quarter ended September 30, 2005. ? Select Financial...

GlycoGenesys Initiates Additional Prestigious Medical Site for GCS-100 Phase I/II Multiple Myeloma Clinical Trial; Patient Scree

GlycoGenesys, Inc. (NASDAQ:GLGS), a biotechnology company, today announced it has initiated Roswell Park Cancer Institute, (RPCI) Buffalo, New York as a clinical site for its Phase I/II dose...

GlycoGenesys to Present at the Bio-Europe 2005 Partnering Conference

GlycoGenesys, Inc. (Nasdaq: GLGS), a biotechnology company, announced today that Frederick E. Pierce, II, VP of Business Development will make a corporate presentation at the Bio-Europe...

GlycoGenesys to Present at the Rodman & Renshaw Techvest 7th Annual Healthcare Conference

GlycoGenesys, Inc.. (Nasdaq: GLGS), a biotechnology company, announced today that John W. Burns, Sr. VP. And CFO will present at the Rodman & Renshaw Techvest 7th Annual Healthcare Conference on...

GlycoGenesys, Inc. Announces $20.0 Million Common Stock Purchase Agreement with Fusion Capital

GlycoGenesys, Inc. (Nasdaq: GLGS), a biotechnology company, today announced it has entered into a common stock purchase agreement with Fusion Capital Fund II, LLC, a Chicago-based institutional...

ChineseWorldNet.com Inc. to Host Global Chinese Financial Forum in Toronto

VANCOUVER, British Columbia, Sept 27 /PRNewswire/ -- ChineseWorldNet.com Inc. is proud to present the third annual Global Chinese Financial Forum (GCFF) -- Toronto Conference 2005 on October...

New Preclinical Discovery Shows GlycoGenesys' Cancer Drug Candidate GCS-100 Inhibits AKT1 (Promoter of Cancer Cell Survival and

Data Presented At The XI International Work Shop on Chronic Lymphocytic Leukemia ? GlycoGenesys, Inc., (NASDAQ: GLGS), a biotechnology company, today announced that Dr. Finbarr Cotter...

New Mechanistic Frame Work For GlycoGenesys' Cancer Drug Candidate GCS-100 Published in The Journal Cancer Research

? GCS-100 Targets Galectin-3 in Multiple Myeloma Cells In Vitro, Leading to Increased Anti-Tumor Activity When Combined With Dexamethasone ? GlycoGenesys, Inc. (NASDAQ:GLGS), a biotechnology...

Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

GLGS - Frequently Asked Questions (FAQ)

What is the current Glycogenesys share price?
The current share price of Glycogenesys is US$ 0,00
What is the 1 year trading range for Glycogenesys share price?
Glycogenesys has traded in the range of US$ 0,00 to US$ 0,00 during the past year
  • Volumen
  • % Tops
  • % Flops
SymbolPreisVol.
BTCTBTC Digital Ltd
US$ 8,2697
(73,73%)
61,45M
BDMDBaird Medical Investment Holdings Ltd
US$ 8,80
(62,36%)
18,63M
CRKNCrown Electrokinetics Corporation
US$ 0,1235
(54,96%)
764,86M
NUKKNukkleus Inc
US$ 29,97
(45,98%)
19,09M
GSITGSI Technology
US$ 3,97
(44,36%)
87,7M
DOGZDogness International Corporation
US$ 18,23
(-58,77%)
740,45k
ORKTOrangeKloud Technology Inc
US$ 3,02
(-24,88%)
21,08M
PMAXPowell Max Ltd
US$ 0,6364
(-23,31%)
4,17M
LGCBLinkage Global Inc
US$ 0,2876
(-22,27%)
890,66k
YYAIConnexa Sports Technologies Inc
US$ 0,8299
(-20,20%)
602,48k
CRKNCrown Electrokinetics Corporation
US$ 0,1235
(54,96%)
764,86M
GCTKGlucoTrack Inc
US$ 0,0852
(15,45%)
465,22M
RIMEAlgorhythm Holdings Inc
US$ 0,0406
(-4,02%)
387,23M
TGLTreasure Global Inc
US$ 0,2459
(14,75%)
267,1M
NVDANVIDIA Corporation
US$ 137,71
(3,10%)
201,4M
Keine Diskussionen Gefunden.
Neuen Thread Erstellen

Kürzlich von Ihnen besucht

Delayed Upgrade Clock